Ultragenyx Announces The Publication Of A Successful 96-Week Randomized, Placebo-Controlled Trial With Crossover Treatment Of Genglycos™ (Also Known As Dtx401) AAV Gene Therapy In GSDIA In The Journal Of Inherited Metabolic Disease
RARE•Publication of 96-week trial results
Sept. 1 (Reuters) - Ultragenyx Pharmaceutical Inc. RARE.O:
- Ultragenyx announces the publication of a successful 96-week randomized, placebo-controlled trial with crossover treatment of Genglycos™ (also known as Dtx401) AAV gene therapy in GSDIA in the Journal of Inherited Metabolic Disease.
Source text: ID:nGNX8dxKzN
Further company coverage: RARE.O
